• Bellecave, P., Gouttenoire, J., Gajer, M., Brass, V., Koutsoudakis, G., Blum, H.E., Bartenschlager, R., Nassal, M., Moradpour, D., 2009. Hepatitis B and C virus coinfection:a novel model system reveals the absence of direct viral interference.Hepatology 50, 46-55.

  • Bertoletti, A., Ferrari, C., 2003. Kinetics of the immune response during HBV and HCV infection. Hepatology 38, 4-13.

  • Blackard, J.T., Sherman, K.E., 2018. Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV). Rev. Med. Virol. 28, e1984.

  • Boni, C., Fisicaro, P., Valdatta, C., Amadei, B., Di Vincenzo, P., Giuberti, T., Laccabue, D., Zerbini, A., Cavalli, A., Missale, G., Bertoletti, A., Ferrari, C., 2007. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection.J. Virol. 81, 4215-4225.

  • Cao, L., Wu, C., Shi, H., Gong, Z., Zhang, E., Wang, H., Zhao, K., Liu, S., Li, S., Gao, X., Wang, Y., Pei, R., Lu, M., Chen, X., 2014. Coexistence of hepatitis B virus quasispecies enhances viral replication and the ability to induce host antibody and cellular immune responses. J. Virol. 88, 8656-8666.

  • Chen, J., Zhao, Y., Zhang, C., Chen, H., Feng, J., Chi, X., Pan, Y., Du, J., Guo, M., Cao, H., Chen, H., Wang, Z., Pei, R., Wang, Q., Pan, L., Niu, J., Chen, X., Tang, H., 2014.Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized mice. Cell Res. 24, 1050-1066.

  • Chen, L.W., Chien, R.N., Yen, C.L., Chang, J.J., Liu, C.J., Lin, C.L., 2010.Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection. J. Gastroenterol. Hepatol. 25, 259-263.

  • Chen, S.Y., Kao, C.F., Chen, C.M., Shih, C.M., Hsu, M.J., Chao, C.H., Wang, S.H., You, L.R., Lee, Y.H., 2003. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J. Biol. Chem. 278, 591-607.

  • Cheng, X., Uchida, T., Xia, Y., Umarova, R., Liu, C.J., Chen, P.J., Gaggar, A., Suri, V., Mucke, M.M., Vermehren, J., Zeuzem, S., Teraoka, Y., Osawa, M., Aikata, H., Tsuji, K., Mori, N., Hige, S., Karino, Y., Imamura, M., Chayama, K., Liang, T.J., 2020.Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. J. Clin. Invest. 130, 3205-3220.Chu, C.J., Lee, S.D., 2008. Hepatitis B virus/hepatitis C virus coinfection:epidemiology, clinical features, viral interactions and treatment. J. Gastroenterol. Hepatol. 23, 512-520.

  • Chu, C.M., Yeh, C.T., Sheen, I.S., Liaw, Y.F., 2002. Acute hepatitis C virus (HCV) infection in chronic carriers of hepatitis B virus (HBV):the impact of underlying active HBV replication on persistence of HCV infection and antibody responses to HCV. Gut 51, 95-99.

  • Eyre, N.S., Phillips, R.J., Bowden, S., Yip, E., Dewar, B., Locarnini, S.A., Beard, M.R., 2009. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J. Hepatol. 51, 446-457.

  • Gish, R.G., 2017. HBV/HCV coinfection and possible reactivation of HBV following DAA use. Gastroenterol. Hepatol. 13, 292-295.

  • Guido, M., Rugge, M., Colombari, R., Cecchetto, A., Scarpa, A., Cadrobbi, P., 1998.Prompt hepatitis C virus suppression following hepatitis B virus superinfection in chronic untreated hepatitis C. Ital. J. Gastroenterol. Hepatol. 30, 414-417.

  • Han, Q., Xu, C., Wu, C., Zhu, W., Yang, R., Chen, X., 2009. Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. Virus Res. 145, 63-73.

  • Heim, M.H., Thimme, R., 2014. Innate and adaptive immune responses in HCV infections.J. Hepatol. 61, S14-S25.

  • Hiraga, N., Imamura, M., Hatakeyama, T., Kitamura, S., Mitsui, F., Tanaka, S., Tsuge, M., Takahashi, S., Abe, H., Maekawa, T., Ochi, H., Tateno, C., Yoshizato, K., Wakita, T., Chayama, K., 2009. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. J. Hepatol. 51, 1046-1054.

  • Huang, L.R., Wu, H.L., Chen, P.J., Chen, D.S., 2006. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc. Natl. Acad. Sci.U. S. A. 103, 17862-17867.

  • Jamma, S., Hussain, G., Lau, D.T., 2010. Current concepts of HBV/HCV coinfection:coexistence, but not necessarily in Harmony. Curr. Hepat. Rep. 9, 260-269.

  • Konstantinou, D., Deutsch, M., 2015. The spectrum of HBV/HCV coinfection:epidemiology, clinical characteristics, viralinteractions and management. Ann.Gastroenterol. 28, 221-228.

  • Li, H., Zhuang, Q.Y., Wang, Y.Z., Zhang, T.Y., Zhao, J.H., Zhang, Y.L., Zhang, J.F., Lin, Y., Yuan, Q., Xia, N.S., Han, J.H., 2014. HBV life cycle is restricted in mouse hepatocytes expressing human NTCP. Cell. Mol. Immunol. 11, 175-183.

  • Liaw, Y.F., Chien, R.N., Lin, S.M., Yeh, C.T., Tsai, S.L., Sheen, I.S., Chu, C.M., 1997.Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J. Interferon Cytokine Res. 17, 449-452.

  • Liu, S., Zhao, K., Su, X., Lu, L., Zhao, H., Zhang, X., Wang, Y., Wu, C., Chen, J., Zhou, Y., Hu, X., Wang, Y., Lu, M., Chen, X., Pei, R., 2017. MITA/STING and its alternative splicing isoform MRP restrict hepatitis B virus replication. PLoS One 12, e0169701.

  • Marot, A., Belaid, A., Orlent, H., Serste, T., Michielsen, P., Colle, I., Laleman, W., de Galocsy, C., Reynaert, H., D'Heygere, F., Moreno, C., Doerig, C., Henrion, J., Deltenre, P., 2017. Characteristics of patients with hepatitis B virus and hepatitis C virus dual infection in a Western European country:comparison with monoinfected patients. Clin Res Hepatol Gastroenterol 41, 656-663.

  • Matsuoka, S., Nirei, K., Tamura, A., Nakamura, H., Matsumura, H., Oshiro, S., Arakawa, Y., Yamagami, H., Tanaka, N., Moriyama, M., 2008. Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology 51, 352-361.

  • Mavilia, M.G., Wu, G.Y., 2018. HBV-HCV coinfection:viral interactions, management, and viral reactivation. J Clin Transl Hepatol 6, 296-305.

  • Micco, L., Peppa, D., Loggi, E., Schurich, A., Jefferson, L., Cursaro, C., Panno, A.M., Bernardi, M., Brander, C., Bihl, F., Andreone, P., Maini, M.K., 2013. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J. Hepatol. 58, 225-233.

  • Murai, K., Hikita, H., Kai, Y., Kondo, Y., Fukuoka, M., Fukutomi, K., Doi, A., Yamai, T., Nakabori, T., Fukuda, R., Takahashi, T., Miyakawa, K., Suemizu, H., Ryo, A., Yamada, R., Kodama, T., Sakamori, R., Tatsumi, T., Takehara, T., 2020. Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway. Sci. Rep. 10, 941.

  • Nattermann, J., Zimmermann, H., Iwan, A., von Lilienfeld-Toal, M., Leifeld, L., Nischalke, H.D., Langhans, B., Sauerbruch, T., Spengler, U., 2006. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology 44, 945-954.

  • Ni, Y., Lempp, F.A., Mehrle, S., Nkongolo, S., Kaufman, C., Falth, M., Stindt, J., Koniger, C., Nassal, M., Kubitz, R., Sultmann, H., Urban, S., 2014. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146, 1070-1083.

  • Raimondo, G., Brunetto, M.R., Pontisso, P., Smedile, A., Maina, A.M., Saitta, C., Squadrito, G., Tono, N., Associazione Italiana Studio Fegato Cooperative Group, 2006. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 43, 100-107.

  • Rodriguez-Inigo, E., Bartolome, J., Ortiz-Movilla, N., Platero, C., Lopez-Alcorocho, J.M., Pardo, M., Castillo, I., Carreno, V., 2005. Hepatitis C virus (HCV) and hepatitis B virus(HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection. J. Virol. 79, 15578-15581.

  • Roy, A., De, A., Singh, V., 2020. DAAs and HBV/HCV coinfection:glimmer of light and a few shades of grey. J. Hepatol. 73, 461.

  • Sagnelli, E., Sagnelli, C., Macera, M., Pisaturo, M., Coppola, N., 2017. An update on the treatment options for HBV/HCV coinfection. Expet Opin. Pharmacother. 18, 1691-1702.

  • Sagnelli, E., Sagnelli, C., Pisaturo, M., Coppola, N., 2014. Hepatic flares in chronic hepatitis C:spontaneous exacerbation vs hepatotropic viruses superinfection. World J. Gastroenterol. 20, 6707-6715.

  • Schuttler, C.G., Fiedler, N., Schmidt, K., Repp, R., Gerlich, W.H., Schaefer, S., 2002.

  • Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein.J. Hepatol. 37, 855-862.

  • Sheen, I.S., Liaw, Y.F., Chu, C.M., Pao, C.C., 1992. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J. Infect. Dis. 165, 831-834.

  • Shen, W.H., Huang, X., Zheng, F.F., Gong, F., Zhu, L., 2020. Changes in circulating follicular helper T cells in peripheral blood of patients with acute hepatitis C virus infection. Ann. Palliat. Med. 9, 3138-3143.

  • Shih, C.M., Chen, C.M., Chen, S.Y., Lee, Y.H., 1995. Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation. J. Virol. 69, 1160-1171.

  • Su, X., Liu, S., Zhang, X., Lam, S.M., Hu, X., Zhou, Y., Chen, J., Wang, Y., Wu, C., Shui, G., Lu, M., Pei, R., Chen, X., 2017. Requirement of cytosolic phospholipase A2 gamma in lipid droplet formation. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1862, 692-705.

  • Tang, L., Chen, C., Gao, X., Zhang, W., Yan, X., Zhou, Y., Guo, L., Zheng, X., Wang, W., Yang, F., Liu, G., Sun, J., Hou, J., Li, Y., 2019. Interleukin 21 reinvigorates the antiviral activity of hepatitis B virus (HBV)-Specific CD8+ T cells in chronic HBV infection. J. Infect. Dis. 219, 750-759.

  • Tseng, C.W., Wu, S.F., Chen, C.Y., Ho, Y.C., He, Y.T., Tseng, K.C., 2020. Characteristics of regulatory T-cell function in patients with chronic hepatitis B and C coinfection.J. Viral Hepat. 27, 800-809.

  • Urbani, S., Boni, C., Amadei, B., Fisicaro, P., Cerioni, S., Valli, M.A., Missale, G., Ferrari, C., 2005. Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology 41, 826-831.

  • Wahle, R.C., Perez, R.M., Pereira, P.F., Oliveira, E.M., Emori, C.T., Uehara, S.N., Silva, I.S., Silva, A.E., Ferraz, M.L., 2015. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection. Braz. J. Infect. Dis. 19, 533-537.

  • Wang, Y., Zhao, C., Zhang, L., Yu, W., Shen, C., Wang, W., Zhen, Z., Zhou, J., 2014. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients. Antivir. Res. 103, 51-59.

  • Welker, R., Hohenberg, H., Tessmer, U., Huckhagel, C., Krausslich, H.G., 2000. Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. J. Virol. 74, 1168-1177.

  • Wiegand, S.B., Jaroszewicz, J., Potthoff, A., Honer Zu Siederdissen, C., Maasoumy, B., Deterding, K., Manns, M.P., Wedemeyer, H., Cornberg, M., 2015. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-gamma-induced protein 10 levels in HBV/HCVcoinfected patients. Clin. Microbiol. Infect. 21, 710 e1-9.

  • Wieland, S.F., Asabe, S., Engle, R.E., Purcell, R.H., Chisari, F.V., 2014. Limited hepatitis B virus replication space in the chronically hepatitis C virus-infected liver. J. Virol. 88, 5184-5188.

  • Wu, J., Huang, S.M., Zhao, X.L., Chen, M.F., Lin, Y., Xia, Y.C., Sun, C., Yang, X.C., Wang, J.Z., Guo, Y., Song, J.J., Zhang, E.J., Wang, B.J., Zheng, X., Schlaak, J.F., Lu, M.J., Yang, D.L., 2014. Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model. J. Virol. 88, 10421-10431.

  • Xia, Y., Cheng, X., Blossey, C.K., Wisskirchen, K., Esser, K., Protzer, U., 2017. Secreted interferon-inducible factors restrict hepatitis B and C virus entry in vitro. J Immunol Res 2017, 4828936.

  • Yang, D., Zuo, C., Wang, X., Meng, X., Xue, B., Liu, N., Yu, R., Qin, Y., Gao, Y., Wang, Q., Hu, J., Wang, L., Zhou, Z., Liu, B., Tan, D., Guan, Y., Zhu, H., 2014. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proc. Natl. Acad. Sci. U. S. A. 111, E1264-E1273.

  • Yang, P.L., Althage, A., Chung, J., Chisari, F.V., 2002. Hydrodynamic injection of viral DNA:a mouse model of acute hepatitis B virus infection. Proc. Natl. Acad. Sci. U. S. A. 99, 13825-13830.

  • Zampino, R., Pisaturo, M.A., Cirillo, G., Marrone, A., Macera, M., Rinaldi, L., Stanzione, M., Durante-Mangoni, E., Gentile, I., Sagnelli, E., Signoriello, G., Miraglia Del Giudice, E., AdinolfI, L.E., Coppola, N., 2015. Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Ann.Hepatol. 14, 75-82.

  • Zarski, J.P., Bohn, B., Bastie, A., Pawlotsky, J.M., Baud, M., Bost-Bezeaux, F., Tran van Nhieu, J., Seigneurin, J.M., Buffet, C., Dhumeaux, D., 1998.Characteristics of patients with dual infection by hepatitis B and C viruses. J. Hepatol. 28, 27-33.

  • Zhang, K., Lai, X., Song, J., He, L., Wang, L., Ou, G., Tian, X., Wang, L., Deng, J., Zhang, J., Li, C., Zhuang, H., Li, T., Xiang, K., 2021. A novel cell culture model reveals the viral interference during hepatitis B and C virus coinfection. Antivir. Res. 189, 105061.

  • Zhao, K., Liu, S., Chen, Y., Yao, Y., Zhou, M., Yuan, Y., Wang, Y., Pei, R., Chen, J., Hu, X., Zhou, Y., Zhao, H., Lu, M., Wu, C., Chen, X., 2018. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg. Microb. Infect. 7, 186.

  • Zhou, M., Zhao, K., Yao, Y., Yuan, Y., Pei, R., Wang, Y., Chen, J., Hu, X., Zhou, Y., Chen, X., Wu, C., 2017. Productive HBV infection of well-differentiated, hNTCPexpressing human hepatoma-derived (Huh7) cells. Virol. Sin. 32, 465-475.

  • Zhu, W., Wu, C., Deng, W., Pei, R., Wang, Y., Cao, L., Qin, B., Lu, M., Chen, X., 2012. Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo. PLoS One 7, e45146.